It is therefore difficult to predict based on the current knowledge how PI3K-Akt-mTOR inhibition will alter the ability of MSCs to communicate and thereby support AML cells in the BM niches through direct cell-cell contact or through their release of soluble mediators. The gene discussed is MTOR; the disease is acute myeloid leukemia.